Haleon plc filings document foreign private issuer disclosures for a global consumer health company whose American depositary shares trade under HLN. Form 6-K reports cover current information such as trading statements, ordinary-share repurchases for cancellation, total voting rights and capital, and annual general meeting poll results.
The filing record also includes debt-market disclosures, including listing particulars for the Euro Medium Term Note programme of Haleon UK Capital plc and Haleon Netherlands Capital B.V. guaranteed by Haleon. Governance and capital-structure disclosures address directors' remuneration, board elections, dividend approvals, special resolutions, ordinary shares, treasury shares, voting rights and shareholder notification thresholds.
Haleon plc (HLN) has commenced a share buyback programme for its £0.01 ordinary shares, with up to £500 million aggregate consideration. Haleon has entered into an irrevocable agreement with Citigroup Global Markets Limited (Citi); purchases will be made on the London Stock Exchange, CBOE Europe Limited and/or Aquis, with Citi making trading decisions independently of Haleon.
The programme will end no later than February 19, 2027. Under the existing AGM Authority, the maximum number of shares that may be purchased is 805,110,900, representing the unused authority as of October 29, 2026. Upon conclusion, approximately 80% of purchased shares will be cancelled; the remainder will be held as treasury shares without voting or dividend rights to meet existing employee share-plan obligations in 2027 and 2028. Haleon states there is no guarantee the programme will be implemented in full.
Haleon plc (HLN) announced that its Q3 trading statement for the year ending December 31, 2026, is available on its investor website and was submitted in full, unedited text to the Financial Conduct Authority’s National Storage Mechanism, where it will shortly be available for inspection.
Chief Executive Officer Brian McNamara and Chief Financial Officer Dawn Allen are scheduled to host a presentation and Q&A at 9:00am GMT (10:00am CET) on October 29, 2026. An archived webcast will be available later that day.
Haleon plc (HLN) reported that, as of September 30, 2026, it had 8,808,341,409 ordinary shares issued, including 11,763,163 treasury shares. The company reported 8,796,578,246 ordinary shares with voting rights; it says shareholders and others with notification obligations should use this figure as the denominator for assessing whether an interest or change in interest must be notified under the FCA’s Disclosure Guidance and Transparency Rules.
Haleon plc (HLN) disclosed acquisitions of ordinary shares through dividend reinvestment by Chief Financial Officer Dawn Allen and Chief Financial Officer Brian McNamara, plus a further transaction entry. On September 22, 2026, Dawn Allen acquired 2,317.19703 shares at £3.44631, and Brian McNamara acquired 12,208.83196 shares at £3.44631.
The further transaction entry reports an acquisition of 2,139.05113 ordinary shares at $9.3801 on September 22, 2026. Each entry identifies dividend reinvestment as the transaction type and the London Stock Exchange as the transaction place.
Haleon plc (HLN) reported a small share transaction by a senior board member. Senior Independent Non-Executive Director Alan Stewart, classified as a Person Discharging Managerial Responsibilities, acquired 242 ordinary shares of Haleon on September 17, 2026 through a dividend reinvestment arrangement.
The shares were purchased at a price of £3.378619 per share on the London Stock Exchange. The disclosure is made in line with the requirements of the UK Market Abuse Regulation governing PDMR dealings in company securities.
Haleon plc (HLN) reported its total voting rights and share capital as of 31 August 2026. The company has 8,808,341,409 ordinary shares of £0.01 each in issue, of which 11,792,625 shares are held as treasury shares. This results in 8,796,548,784 ordinary shares with voting rights, which shareholders and other obliged investors should use as the denominator when calculating whether they must notify interests or changes in interests under the FCA's Disclosure Guidance and Transparency Rules.
Haleon plc (HLN) reports that its subsidiary Haleon US Capital LLC has established new senior debt securities under an indenture dated August 21, 2026 among Haleon plc, Haleon US Capital LLC, Haleon UK Capital plc and Deutsche Bank Trust Company Americas as trustee. An officer’s certificate sets the terms for three series: 4.625% Senior Fixed Rate Notes due 2029, 4.875% Senior Fixed Rate Notes due 2031, and 5.375% Senior Fixed Rate Notes due 2036, each with related guarantees and note forms filed as exhibits. An underwriting agreement dated August 12, 2026 with a syndicate of investment banks and related legal opinions and consents are also included and incorporated by reference into Haleon’s existing Form F-3 and Form S-8 registration statements.
Haleon plc (HLN) reports that its wholly owned subsidiary Haleon US Capital LLC has set the pricing terms, expiration and results for a cash tender offer to repurchase any and all of its outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027.
The company directs investors to a detailed announcement hosted by the London Stock Exchange and Haleon’s investor website, and notes that the full text has been submitted to the UK Financial Conduct Authority’s National Storage Mechanism for public inspection.
Haleon plc (HLN) reports progress and completion of its share repurchase activity under the £500m buyback programme announced on 12 March 2026. On 17 and 18 August 2026, the company purchased a total of 1,569,800 ordinary shares of £0.01 each for cancellation across the London Stock Exchange and CBOE UK venues, at volume-weighted average prices around 352p per share.
After settlement of these purchases, Haleon’s registered share capital is 8,808,341,409 ordinary shares, including 11,807,443 treasury shares, leaving 8,796,533,966 shares with voting rights. Since the start of 2026, Haleon has repurchased 144,012,239 shares, all of which were cancelled, and confirms that the £500m share buyback programme is now complete.
Haleon plc reported purchases of 10,995,213 ordinary shares of £0.01 for cancellation under its share buyback programme announced on 12 March 2026. The shares were bought on UK venues including the London Stock Exchange, CBOE (UK) platforms and Aquis between 11 and 13 August 2026.
After settlement, Haleon’s registered share capital is 8,809,911,209 ordinary shares, of which 11,807,443 are held as treasury shares. The number of ordinary shares with voting rights is 8,798,103,766, a figure shareholders may use for FCA disclosure threshold calculations.